Christoph Nowak
Hoofd Techniek/Wetenschap/O&O bij DIAMYD MEDICAL AB
Vermogen: 581 $ op 30-04-2024
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Anders Essen-Möller | M | 83 | 28 jaar | |
Markus Jerling | M | 72 | 3 jaar | |
Ulf Hannelius | M | 49 | 8 jaar | |
Erik Kjellsson Nerpin | M | 63 | 12 jaar | |
Daniel Ehrenstråhle | M | 50 | 1 jaar | |
Mark Atkinson | M | 63 | 6 jaar | |
Martina Widman | F | 43 | 8 jaar | |
Niclas Holmgren | M | 32 | 1 jaar | |
Karin Hehenberger | M | 52 | 3 jaar | |
Carl Torbjörn Bäckström | M | 76 | 7 jaar | |
Michael Owens | M | 68 | 1 jaar | |
Anna Styrud | F | 63 | 14 jaar | |
Theresa Comiskey Olsen | F | 61 |
Melius Pharma AB
Melius Pharma AB Pharmaceuticals: MajorHealth Technology Melius Pharma AB is a Swedish clinical stage pharmaceutical company that develops new treatments for chronic cough in idiopathic pulmonary fibrosis (IPF) patients. The company is based in Lund, Sweden and is privately owned, benefiting from the support of two of Sweden's most prominent professional life science investors who bring expertise to develop the company. IPF is a chronic, progressive lung inflammation characterized by fibrosis and disruption of normal lung architecture. Melius Pharma has developed ME-015, which stabilizes ion channels in the neuronal endings in the lungs that mediate cough. ME-015 is presumed to have an acute effect and is a solution for chronic cough, which is one of the major symptoms experienced by 80%% of IPF patients. | - |
Maria-Teresa Essen-Möller | F | 54 | 15 jaar | |
Anton Lindqvist | M | 44 | 11 jaar | |
Karin Rosen | M | 57 | 1 jaar | |
Eva Karlström | F | 60 | 4 jaar | |
Stian Kildal | M | - | 1 jaar | |
Kristofer Svensson | M | - |
Melius Pharma AB
Melius Pharma AB Pharmaceuticals: MajorHealth Technology Melius Pharma AB is a Swedish clinical stage pharmaceutical company that develops new treatments for chronic cough in idiopathic pulmonary fibrosis (IPF) patients. The company is based in Lund, Sweden and is privately owned, benefiting from the support of two of Sweden's most prominent professional life science investors who bring expertise to develop the company. IPF is a chronic, progressive lung inflammation characterized by fibrosis and disruption of normal lung architecture. Melius Pharma has developed ME-015, which stabilizes ion channels in the neuronal endings in the lungs that mediate cough. ME-015 is presumed to have an acute effect and is a solution for chronic cough, which is one of the major symptoms experienced by 80%% of IPF patients. | 2 jaar |
Lars Christer Fedrik Fåhraeus | M | 59 |
Melius Pharma AB
Melius Pharma AB Pharmaceuticals: MajorHealth Technology Melius Pharma AB is a Swedish clinical stage pharmaceutical company that develops new treatments for chronic cough in idiopathic pulmonary fibrosis (IPF) patients. The company is based in Lund, Sweden and is privately owned, benefiting from the support of two of Sweden's most prominent professional life science investors who bring expertise to develop the company. IPF is a chronic, progressive lung inflammation characterized by fibrosis and disruption of normal lung architecture. Melius Pharma has developed ME-015, which stabilizes ion channels in the neuronal endings in the lungs that mediate cough. ME-015 is presumed to have an acute effect and is a solution for chronic cough, which is one of the major symptoms experienced by 80%% of IPF patients. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Paul de Potocki | M | 62 | 2 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Zweden | 21 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Christoph Nowak
- Persoonlijk netwerk